WO2009022761A1 - Dissolvable nano web porous film and method of preparing the same - Google Patents
Dissolvable nano web porous film and method of preparing the same Download PDFInfo
- Publication number
- WO2009022761A1 WO2009022761A1 PCT/KR2007/004342 KR2007004342W WO2009022761A1 WO 2009022761 A1 WO2009022761 A1 WO 2009022761A1 KR 2007004342 W KR2007004342 W KR 2007004342W WO 2009022761 A1 WO2009022761 A1 WO 2009022761A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agents
- porous film
- derivatives
- nano
- film
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 63
- 229920000642 polymer Polymers 0.000 claims abstract description 72
- 239000002121 nanofiber Substances 0.000 claims abstract description 58
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 239000004014 plasticizer Substances 0.000 claims abstract description 23
- 238000009987 spinning Methods 0.000 claims abstract description 20
- 238000001035 drying Methods 0.000 claims abstract description 19
- 239000003349 gelling agent Substances 0.000 claims abstract description 19
- 239000000654 additive Substances 0.000 claims abstract description 18
- 230000000996 additive effect Effects 0.000 claims abstract description 4
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 51
- 239000003814 drug Substances 0.000 claims description 37
- -1 elsinan Polymers 0.000 claims description 37
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 25
- 229920002472 Starch Polymers 0.000 claims description 24
- 239000000463 material Substances 0.000 claims description 22
- 239000008107 starch Substances 0.000 claims description 22
- 235000019698 starch Nutrition 0.000 claims description 22
- 229920000161 Locust bean gum Polymers 0.000 claims description 20
- 235000010420 locust bean gum Nutrition 0.000 claims description 20
- 239000000711 locust bean gum Substances 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 16
- 239000004373 Pullulan Substances 0.000 claims description 14
- 229920001218 Pullulan Polymers 0.000 claims description 14
- 239000000796 flavoring agent Substances 0.000 claims description 14
- 235000019423 pullulan Nutrition 0.000 claims description 14
- 229930006000 Sucrose Natural products 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 13
- 210000003296 saliva Anatomy 0.000 claims description 13
- 239000005720 sucrose Substances 0.000 claims description 13
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 12
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 12
- 235000010418 carrageenan Nutrition 0.000 claims description 12
- 229920001525 carrageenan Polymers 0.000 claims description 12
- 239000000679 carrageenan Substances 0.000 claims description 12
- 229940113118 carrageenan Drugs 0.000 claims description 12
- 235000010356 sorbitol Nutrition 0.000 claims description 12
- 239000000600 sorbitol Substances 0.000 claims description 12
- 229920001285 xanthan gum Polymers 0.000 claims description 12
- 235000010493 xanthan gum Nutrition 0.000 claims description 12
- 239000000230 xanthan gum Substances 0.000 claims description 12
- 229940082509 xanthan gum Drugs 0.000 claims description 12
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 11
- 239000000194 fatty acid Substances 0.000 claims description 11
- 229930195729 fatty acid Natural products 0.000 claims description 11
- 235000013772 propylene glycol Nutrition 0.000 claims description 11
- 235000015165 citric acid Nutrition 0.000 claims description 10
- 235000019441 ethanol Nutrition 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 229940088598 enzyme Drugs 0.000 claims description 9
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 8
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 8
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 8
- 239000000306 component Substances 0.000 claims description 8
- 229940041616 menthol Drugs 0.000 claims description 8
- 229920000609 methyl cellulose Polymers 0.000 claims description 8
- 235000010981 methylcellulose Nutrition 0.000 claims description 8
- 239000001923 methylcellulose Substances 0.000 claims description 8
- 239000001814 pectin Substances 0.000 claims description 8
- 229920001277 pectin Polymers 0.000 claims description 8
- 235000010987 pectin Nutrition 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 7
- 239000001856 Ethyl cellulose Substances 0.000 claims description 6
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 6
- 229920002907 Guar gum Polymers 0.000 claims description 6
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 239000002269 analeptic agent Substances 0.000 claims description 6
- 239000000935 antidepressant agent Substances 0.000 claims description 6
- 229940005513 antidepressants Drugs 0.000 claims description 6
- 239000004599 antimicrobial Substances 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 238000001523 electrospinning Methods 0.000 claims description 6
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 6
- 229920001249 ethyl cellulose Polymers 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 239000003205 fragrance Substances 0.000 claims description 6
- 235000010417 guar gum Nutrition 0.000 claims description 6
- 239000000665 guar gum Substances 0.000 claims description 6
- 229960002154 guar gum Drugs 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 239000000049 pigment Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 150000003212 purines Chemical class 0.000 claims description 6
- 229940124530 sulfonamide Drugs 0.000 claims description 6
- 150000003456 sulfonamides Chemical class 0.000 claims description 6
- 229940124549 vasodilator Drugs 0.000 claims description 6
- 239000003071 vasodilator agent Substances 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 229940014259 gelatin Drugs 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- 229920002148 Gellan gum Polymers 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 108010051696 Growth Hormone Proteins 0.000 claims description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 235000014749 Mentha crispa Nutrition 0.000 claims description 4
- 229930182555 Penicillin Natural products 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 102100038803 Somatotropin Human genes 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 239000004098 Tetracycline Substances 0.000 claims description 4
- 235000010489 acacia gum Nutrition 0.000 claims description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 4
- 239000003098 androgen Substances 0.000 claims description 4
- 229940030486 androgens Drugs 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 239000000730 antalgic agent Substances 0.000 claims description 4
- 229940046836 anti-estrogen Drugs 0.000 claims description 4
- 230000001833 anti-estrogenic effect Effects 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 229940125681 anticonvulsant agent Drugs 0.000 claims description 4
- 239000001961 anticonvulsive agent Substances 0.000 claims description 4
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- 239000003429 antifungal agent Substances 0.000 claims description 4
- 239000003435 antirheumatic agent Substances 0.000 claims description 4
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 claims description 4
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 4
- 210000000941 bile Anatomy 0.000 claims description 4
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims description 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 4
- 239000003086 colorant Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 239000000328 estrogen antagonist Substances 0.000 claims description 4
- 239000003925 fat Substances 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 4
- 235000011087 fumaric acid Nutrition 0.000 claims description 4
- 239000000417 fungicide Substances 0.000 claims description 4
- 229930182830 galactose Natural products 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 235000001727 glucose Nutrition 0.000 claims description 4
- 239000000122 growth hormone Substances 0.000 claims description 4
- 150000002357 guanidines Chemical class 0.000 claims description 4
- 150000002429 hydrazines Chemical class 0.000 claims description 4
- 150000002460 imidazoles Chemical class 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- CKFGINPQOCXMAZ-UHFFFAOYSA-N methanediol Chemical compound OCO CKFGINPQOCXMAZ-UHFFFAOYSA-N 0.000 claims description 4
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 150000004885 piperazines Chemical class 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 4
- 150000007660 quinolones Chemical class 0.000 claims description 4
- 239000000021 stimulant Substances 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- 235000019364 tetracycline Nutrition 0.000 claims description 4
- 150000003522 tetracyclines Chemical class 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- 239000005495 thyroid hormone Substances 0.000 claims description 4
- 229940036555 thyroid hormone Drugs 0.000 claims description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 claims description 3
- 150000003973 alkyl amines Chemical class 0.000 claims description 3
- 230000002280 anti-androgenic effect Effects 0.000 claims description 3
- 239000000051 antiandrogen Substances 0.000 claims description 3
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229960004676 antithrombotic agent Drugs 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 239000003456 ion exchange resin Substances 0.000 claims description 3
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 3
- 230000000873 masking effect Effects 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 235000019198 oils Nutrition 0.000 claims description 3
- 150000002894 organic compounds Chemical class 0.000 claims description 3
- 150000002990 phenothiazines Chemical class 0.000 claims description 3
- 239000000419 plant extract Substances 0.000 claims description 3
- 229920005862 polyol Polymers 0.000 claims description 3
- 150000003077 polyols Chemical class 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical class CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 claims description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 2
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 claims description 2
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 claims description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920001685 Amylomaize Polymers 0.000 claims description 2
- 229920000856 Amylose Polymers 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- 229940123208 Biguanide Drugs 0.000 claims description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- 229930186147 Cephalosporin Natural products 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 101800001982 Cholecystokinin Proteins 0.000 claims description 2
- 102100025841 Cholecystokinin Human genes 0.000 claims description 2
- 102000003914 Cholinesterases Human genes 0.000 claims description 2
- 108090000322 Cholinesterases Proteins 0.000 claims description 2
- 241000157855 Cinchona Species 0.000 claims description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 claims description 2
- 101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 229920002261 Corn starch Polymers 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 2
- 239000004278 EU approved seasoning Substances 0.000 claims description 2
- 229940127463 Enzyme Inducers Drugs 0.000 claims description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
- 108010022355 Fibroins Proteins 0.000 claims description 2
- 229920001503 Glucan Polymers 0.000 claims description 2
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 claims description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 2
- 102000006771 Gonadotropins Human genes 0.000 claims description 2
- 108010086677 Gonadotropins Proteins 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 208000001953 Hypotension Diseases 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 244000246386 Mentha pulegium Species 0.000 claims description 2
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 2
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims description 2
- 241000244206 Nematoda Species 0.000 claims description 2
- 229930193140 Neomycin Natural products 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000006 Nitroglycerin Substances 0.000 claims description 2
- 241000266501 Ormosia ormondii Species 0.000 claims description 2
- 241000935974 Paralichthys dentatus Species 0.000 claims description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 2
- 102000057297 Pepsin A Human genes 0.000 claims description 2
- 108090000284 Pepsin A Proteins 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 102000003946 Prolactin Human genes 0.000 claims description 2
- 108010057464 Prolactin Proteins 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- 206010038776 Retching Diseases 0.000 claims description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 2
- 241000242678 Schistosoma Species 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 2
- 241000244155 Taenia Species 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 2
- 229940116731 Uricosuric agent Drugs 0.000 claims description 2
- 240000004922 Vigna radiata Species 0.000 claims description 2
- 235000010721 Vigna radiata var radiata Nutrition 0.000 claims description 2
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 108010046377 Whey Proteins Proteins 0.000 claims description 2
- 102000007544 Whey Proteins Human genes 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 229960005305 adenosine Drugs 0.000 claims description 2
- 235000011037 adipic acid Nutrition 0.000 claims description 2
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims description 2
- 239000000808 adrenergic beta-agonist Substances 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 235000010419 agar Nutrition 0.000 claims description 2
- 239000003732 agents acting on the eye Substances 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 239000003288 aldose reductase inhibitor Substances 0.000 claims description 2
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 claims description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 claims description 2
- 230000002152 alkylating effect Effects 0.000 claims description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-M all-trans-retinoate Chemical compound [O-]C(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-M 0.000 claims description 2
- 239000002160 alpha blocker Substances 0.000 claims description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 229940126575 aminoglycoside Drugs 0.000 claims description 2
- 229940072174 amphenicols Drugs 0.000 claims description 2
- 229940124325 anabolic agent Drugs 0.000 claims description 2
- 239000003263 anabolic agent Substances 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 claims description 2
- 229940035674 anesthetics Drugs 0.000 claims description 2
- 230000000954 anitussive effect Effects 0.000 claims description 2
- 230000000507 anthelmentic effect Effects 0.000 claims description 2
- 229940124339 anthelmintic agent Drugs 0.000 claims description 2
- 239000000921 anthelmintic agent Substances 0.000 claims description 2
- 239000000058 anti acne agent Substances 0.000 claims description 2
- 230000000398 anti-amebic effect Effects 0.000 claims description 2
- 230000002456 anti-arthritic effect Effects 0.000 claims description 2
- 230000001142 anti-diarrhea Effects 0.000 claims description 2
- 230000001384 anti-glaucoma Effects 0.000 claims description 2
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 2
- 230000001741 anti-phlogistic effect Effects 0.000 claims description 2
- 230000003473 anti-pneumocystis Effects 0.000 claims description 2
- 230000001754 anti-pyretic effect Effects 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- 230000002785 anti-thrombosis Effects 0.000 claims description 2
- 230000001572 anti-trichomonad Effects 0.000 claims description 2
- 229940124340 antiacne agent Drugs 0.000 claims description 2
- 239000000043 antiallergic agent Substances 0.000 claims description 2
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 229940125708 antidiabetic agent Drugs 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 229940125714 antidiarrheal agent Drugs 0.000 claims description 2
- 239000003793 antidiarrheal agent Substances 0.000 claims description 2
- 229940124538 antidiuretic agent Drugs 0.000 claims description 2
- 239000003160 antidiuretic agent Substances 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 229940127088 antihypertensive drug Drugs 0.000 claims description 2
- 229940124572 antihypotensive agent Drugs 0.000 claims description 2
- 239000003430 antimalarial agent Substances 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 claims description 2
- 229940124433 antimigraine drug Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 claims description 2
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 239000003101 antineoplastic hormone agonist and antagonist Substances 0.000 claims description 2
- 239000000939 antiparkinson agent Substances 0.000 claims description 2
- 239000002221 antipyretic Substances 0.000 claims description 2
- 229940125716 antipyretic agent Drugs 0.000 claims description 2
- 229940111121 antirheumatic drug quinolines Drugs 0.000 claims description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 claims description 2
- 239000003434 antitussive agent Substances 0.000 claims description 2
- 229940124584 antitussives Drugs 0.000 claims description 2
- 239000003699 antiulcer agent Substances 0.000 claims description 2
- 239000003709 antiurolithiasis agent Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 239000002249 anxiolytic agent Substances 0.000 claims description 2
- 230000000949 anxiolytic effect Effects 0.000 claims description 2
- 239000002830 appetite depressant Substances 0.000 claims description 2
- 239000003886 aromatase inhibitor Substances 0.000 claims description 2
- 229940046844 aromatase inhibitors Drugs 0.000 claims description 2
- 239000008122 artificial sweetener Substances 0.000 claims description 2
- 235000021311 artificial sweeteners Nutrition 0.000 claims description 2
- 150000003975 aryl alkyl amines Chemical class 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000000305 astragalus gummifer gum Substances 0.000 claims description 2
- 150000001541 aziridines Chemical class 0.000 claims description 2
- 229940125717 barbiturate Drugs 0.000 claims description 2
- 229940049706 benzodiazepine Drugs 0.000 claims description 2
- 150000007658 benzothiadiazines Chemical class 0.000 claims description 2
- 239000002876 beta blocker Substances 0.000 claims description 2
- 229940030611 beta-adrenergic blocking agent Drugs 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 150000004283 biguanides Chemical class 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 150000001649 bromium compounds Chemical class 0.000 claims description 2
- 229940124630 bronchodilator Drugs 0.000 claims description 2
- 239000000168 bronchodilator agent Substances 0.000 claims description 2
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000000480 calcium channel blocker Substances 0.000 claims description 2
- 229940041011 carbapenems Drugs 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000000496 cardiotonic agent Substances 0.000 claims description 2
- 239000005018 casein Substances 0.000 claims description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 2
- 235000021240 caseins Nutrition 0.000 claims description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000005487 catechin Nutrition 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 229940124587 cephalosporin Drugs 0.000 claims description 2
- 150000001780 cephalosporins Chemical class 0.000 claims description 2
- 210000004720 cerebrum Anatomy 0.000 claims description 2
- 239000013522 chelant Substances 0.000 claims description 2
- 229940107137 cholecystokinin Drugs 0.000 claims description 2
- 239000000812 cholinergic antagonist Substances 0.000 claims description 2
- 229940048961 cholinesterase Drugs 0.000 claims description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 2
- 229950001002 cianidanol Drugs 0.000 claims description 2
- TXCGAZHTZHNUAI-UHFFFAOYSA-N clofibric acid Chemical class OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 TXCGAZHTZHNUAI-UHFFFAOYSA-N 0.000 claims description 2
- 239000005515 coenzyme Substances 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 235000005822 corn Nutrition 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 229940099112 cornstarch Drugs 0.000 claims description 2
- 210000004351 coronary vessel Anatomy 0.000 claims description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims description 2
- 239000003712 decolorant Substances 0.000 claims description 2
- 239000000850 decongestant Substances 0.000 claims description 2
- 229940124581 decongestants Drugs 0.000 claims description 2
- 208000002925 dental caries Diseases 0.000 claims description 2
- 102000038379 digestive enzymes Human genes 0.000 claims description 2
- 108091007734 digestive enzymes Proteins 0.000 claims description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 2
- 150000002016 disaccharides Chemical class 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 claims description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 244000078703 ectoparasite Species 0.000 claims description 2
- 239000003172 expectorant agent Substances 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical class C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 2
- 235000011194 food seasoning agent Nutrition 0.000 claims description 2
- 235000019256 formaldehyde Nutrition 0.000 claims description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 2
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 2
- 150000002238 fumaric acids Chemical class 0.000 claims description 2
- 230000000855 fungicidal effect Effects 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 239000007789 gas Substances 0.000 claims description 2
- 230000027119 gastric acid secretion Effects 0.000 claims description 2
- 235000010492 gellan gum Nutrition 0.000 claims description 2
- 239000000216 gellan gum Substances 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- 239000001087 glyceryl triacetate Substances 0.000 claims description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 2
- 230000001456 gonadotroph Effects 0.000 claims description 2
- 239000002622 gonadotropin Substances 0.000 claims description 2
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002366 halogen compounds Chemical class 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 239000002607 heparin antagonist Substances 0.000 claims description 2
- 235000001050 hortel pimenta Nutrition 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 229960001067 hydrocortisone acetate Drugs 0.000 claims description 2
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims description 2
- 239000005555 hypertensive agent Substances 0.000 claims description 2
- 208000021822 hypotensive Diseases 0.000 claims description 2
- 230000001077 hypotensive effect Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 2
- 229960000367 inositol Drugs 0.000 claims description 2
- 229940047124 interferons Drugs 0.000 claims description 2
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 150000003951 lactams Chemical class 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 claims description 2
- 229940041028 lincosamides Drugs 0.000 claims description 2
- 229940040504 lipotropic agent Drugs 0.000 claims description 2
- 239000003912 lipotropic agent Substances 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 239000002445 liver protective agent Substances 0.000 claims description 2
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 2
- 229940041033 macrolides Drugs 0.000 claims description 2
- 235000020429 malt syrup Nutrition 0.000 claims description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 2
- 229960004961 mechlorethamine Drugs 0.000 claims description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 239000002395 mineralocorticoid Substances 0.000 claims description 2
- 239000003604 miotic agent Substances 0.000 claims description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 2
- 229940066491 mucolytics Drugs 0.000 claims description 2
- 229940035363 muscle relaxants Drugs 0.000 claims description 2
- 239000003158 myorelaxant agent Substances 0.000 claims description 2
- 239000003887 narcotic antagonist Substances 0.000 claims description 2
- 230000003533 narcotic effect Effects 0.000 claims description 2
- 229960004927 neomycin Drugs 0.000 claims description 2
- 239000004090 neuroprotective agent Substances 0.000 claims description 2
- 239000002661 non steroidal estrogen Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 239000002664 nootropic agent Substances 0.000 claims description 2
- 230000001777 nootropic effect Effects 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 229940125702 ophthalmic agent Drugs 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 239000002863 oxytocic agent Substances 0.000 claims description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 2
- 239000000734 parasympathomimetic agent Substances 0.000 claims description 2
- 229940127242 parasympathomimetic drug Drugs 0.000 claims description 2
- 229940049954 penicillin Drugs 0.000 claims description 2
- 150000002960 penicillins Chemical class 0.000 claims description 2
- 235000019477 peppermint oil Nutrition 0.000 claims description 2
- 229940111202 pepsin Drugs 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 210000000578 peripheral nerve Anatomy 0.000 claims description 2
- 230000002572 peristaltic effect Effects 0.000 claims description 2
- 150000002989 phenols Chemical class 0.000 claims description 2
- 150000005458 piperidinediones Chemical class 0.000 claims description 2
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 150000004291 polyenes Chemical class 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 2
- 235000013824 polyphenols Nutrition 0.000 claims description 2
- 229920001592 potato starch Polymers 0.000 claims description 2
- 229940116317 potato starch Drugs 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 239000000583 progesterone congener Substances 0.000 claims description 2
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 claims description 2
- 229940097325 prolactin Drugs 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- 201000004240 prostatic hypertrophy Diseases 0.000 claims description 2
- 239000003223 protective agent Substances 0.000 claims description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims description 2
- 239000002423 protozoacide Substances 0.000 claims description 2
- 150000003195 pteridines Chemical class 0.000 claims description 2
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 claims description 2
- 150000003217 pyrazoles Chemical class 0.000 claims description 2
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims description 2
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 claims description 2
- 150000004040 pyrrolidinones Chemical class 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000003410 quininyl group Chemical group 0.000 claims description 2
- 150000003248 quinolines Chemical class 0.000 claims description 2
- 239000003488 releasing hormone Substances 0.000 claims description 2
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical class O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 claims description 2
- 239000003169 respiratory stimulant agent Substances 0.000 claims description 2
- 229940066293 respiratory stimulants Drugs 0.000 claims description 2
- 229940100486 rice starch Drugs 0.000 claims description 2
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 claims description 2
- 150000003872 salicylic acid derivatives Chemical class 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 2
- 229940125723 sedative agent Drugs 0.000 claims description 2
- 239000000932 sedative agent Substances 0.000 claims description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 229940071440 soy protein isolate Drugs 0.000 claims description 2
- 230000003637 steroidlike Effects 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 235000011044 succinic acid Nutrition 0.000 claims description 2
- 150000005846 sugar alcohols Chemical class 0.000 claims description 2
- 150000003457 sulfones Chemical class 0.000 claims description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 2
- 229940066768 systemic antihistamines aminoalkyl ethers Drugs 0.000 claims description 2
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 claims description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 229940040944 tetracyclines Drugs 0.000 claims description 2
- 150000005075 thioxanthenes Chemical class 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 229960002622 triacetin Drugs 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- HFFLGKNGCAIQMO-UHFFFAOYSA-N trichloroacetaldehyde Chemical class ClC(Cl)(Cl)C=O HFFLGKNGCAIQMO-UHFFFAOYSA-N 0.000 claims description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims description 2
- 239000001069 triethyl citrate Substances 0.000 claims description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000013769 triethyl citrate Nutrition 0.000 claims description 2
- 229940116269 uric acid Drugs 0.000 claims description 2
- 239000003383 uricosuric agent Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940100445 wheat starch Drugs 0.000 claims description 2
- 235000021119 whey protein Nutrition 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 150000003952 β-lactams Chemical class 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 244000024873 Mentha crispa Species 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000002255 antigout agent Substances 0.000 claims 1
- 229960002708 antigout preparations Drugs 0.000 claims 1
- 229940030999 antipsoriatics Drugs 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 229940094892 gonadotropins Drugs 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 229940047122 interleukins Drugs 0.000 claims 1
- 229950000688 phenothiazine Drugs 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 150000003873 salicylate salts Chemical class 0.000 claims 1
- 230000000580 secretagogue effect Effects 0.000 claims 1
- 229960000103 thrombolytic agent Drugs 0.000 claims 1
- 239000000155 melt Substances 0.000 abstract description 4
- 239000010408 film Substances 0.000 description 232
- 210000000214 mouth Anatomy 0.000 description 40
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 24
- 239000004615 ingredient Substances 0.000 description 23
- 230000008569 process Effects 0.000 description 17
- 239000012153 distilled water Substances 0.000 description 14
- 235000019634 flavors Nutrition 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 9
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 8
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 8
- 108010011485 Aspartame Proteins 0.000 description 8
- 239000000619 acesulfame-K Substances 0.000 description 8
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 8
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 8
- 239000000605 aspartame Substances 0.000 description 8
- 235000010357 aspartame Nutrition 0.000 description 8
- 229960003438 aspartame Drugs 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 239000001630 malic acid Substances 0.000 description 8
- 235000011090 malic acid Nutrition 0.000 description 8
- 229940099690 malic acid Drugs 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 230000006641 stabilisation Effects 0.000 description 6
- 238000011105 stabilization Methods 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 238000001878 scanning electron micrograph Methods 0.000 description 5
- 230000005684 electric field Effects 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000002075 main ingredient Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000005913 Maltodextrin Substances 0.000 description 3
- 244000078639 Mentha spicata Species 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000007599 discharging Methods 0.000 description 3
- 238000010041 electrostatic spinning Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 244000144730 Amygdalus persica Species 0.000 description 2
- 206010006326 Breath odour Diseases 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000008204 material by function Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000008368 mint flavor Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008373 coffee flavor Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- STTADZBLEUMJRG-IKNOHUQMSA-N dextromethorphan hydrobromide Chemical compound O.Br.C([C@@H]12)CCC[C@]11CCN(C)[C@H]2CC2=CC=C(OC)C=C21 STTADZBLEUMJRG-IKNOHUQMSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229920006280 packaging film Polymers 0.000 description 1
- 239000012785 packaging film Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000007382 vortex spinning Methods 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F1/00—General methods for the manufacture of artificial filaments or the like
- D01F1/02—Addition of substances to the spinning solution or to the melt
- D01F1/10—Other agents for modifying properties
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a dissolvable nano web porous film that is biologically or physiologically applicable, and a method of preparing the same. More particularly, the present invention relates to a nano web porous film that has a nano web network structure and a large specific surface area and a method of preparing the same.
- conventional edible nonporous films are produced in such a fashion of: dissolving polymers such as starch, pullulan, etc., and materials which include film forming agents, plasticizer, flavoring agents, sulfur precipitating agents, saliva stimulating agents, cooling agents, surfactants, stabilizing agents, emulsifying agents, thickening agents, binding agents, coloring agents, pigments, sweeteners, fragrances, antimicrobial agents, etc. in a solvent such as water to provide a mixture thereof; forming the mixture into a film, followed by drying the film; cutting the obtained film to pieces of the film having a proper size; and putting them in a container.
- dissolving polymers such as starch, pullulan, etc.
- materials which include film forming agents, plasticizer, flavoring agents, sulfur precipitating agents, saliva stimulating agents, cooling agents, surfactants, stabilizing agents, emulsifying agents, thickening agents, binding agents, coloring agents, pigments, sweeteners, fragrances, antimicrobial agents, etc. in a solvent such as water
- the conventional edible nonporous films require excellent dissolvability in a mouth such that the films are easily liquefied in the mouth, and drying resistance whereby the films are not cracked or curled. Further, the films should not become sticky due to absorption of moisture or heat.
- Such a thin nonporous film tends to absorb moisture, which causes sticking of the film.
- the film tends to absorb moisture or tends to be dissolved at high temperature and humidity, and thus it can easily become sticky in the summer.
- JP Patent Publication No. 1999-116469 disclose a film capable of being quickly dissolved in the mouth.
- JP Patent Publication No. 1993-236885 discloses an edible film as a vehicle to carry flavoring and refreshing food without attracting public attention, and a film that contains pullulan and carrageenan to improve drying resistance.
- these films have low resistance to moisture and suffer from sticking in highly humid conditions.
- US Patent No. 3,784,390 discloses pullulan films and their use in coating and packing materials for foods, pharmaceuticals and other oxygen sensitive materials.
- US Patent No. 4,623,394 discloses a method of preparing a film with pullulan.
- US Patent No. 7,067,116 discloses products of edible films which include pullulan binders, polysaccharides, antibacterial agents, flavor-imparting agents, and pharmaceutically active components.
- US Patent No. 6,528,088 discloses a film that contains modified starch, such as etherified starch or esterified starch, and plasticizers mixed with the starch in the ratio of at least 0.5: 1 by weight to increase the plasticity of the film.
- modified starch such as etherified starch or esterified starch
- plasticizers mixed with the starch in the ratio of at least 0.5: 1 by weight to increase the plasticity of the film.
- a high plasticizer content of the film causes an unpleasant feeling in the mouth and insufficient sticking resistance.
- US Patent No. 6,656,493 discloses a film that contains sodium alginate and mal- todextrin. Maltodextrin having a low molecular weight is added to the films to improve dissolution in the oral cavity. However, as the concentration of maltodextrin increases, moisture resistance of the film decreases, causing easy sticking thereof. The drying resistance of the films is also not satisfactory.
- US Patent Application Publication No. 2003/0099692 discloses a film that includes processed starch as a main ingredient.
- the starch is cross-linked and chemically processed as in acetyl, ester, hydroxyethyl and hydroxyproply derivatives of starch. Further, derivatives of starch by oxidation, enzyme conversion, acid hydrolysis, etc. may also be used in forming the film.
- the processed starch is substantially independently used, and thus the film does not have sufficient sticking resistance.
- WO 98/26763 discloses a film for use in the oral cavity, which may contain a cosmetic or pharmaceutical active component
- WO 01/70194 discloses a rapidly dissolvable edible film that contains an ion exchange resin as a taste masking agent
- WO 98/20862 also discloses a film for use in the oral cavity, which may contain a cosmetic or pharmaceutical active component
- WO 99/17753 discloses a rapidly soluble film for delivering medical supplies to be absorbed in a digestive tract
- US Patent No. 6,596,290 discloses the delivery of pharmaceutical agents in an edible film vehicle.
- US Patent No. 5,935,883 discloses a process of producing a superfine microfiber split web using a melt-blown device.
- US Patent No. 6,057,256 discloses formation of a coherent entangled web by blowing a polymer solution in a collector.
- US Patent No. 6,106,913 discloses a web produced with a fiber of 1 nm using the combination of an electro spinning method and an air vortex spinning method.
- US Patent No. 6,110,509 discloses a biodegradable silk web having a diameter ranging from 2 to 2000 nm using an electro spinning method.
- KR patent publication No. 2001-0031586 discloses a process of massively preparing a nano-sized nanofiber web by organically combining a melt-blown method and an electrostatic spinning method.
- KR patent publication No. 2001-0031587 discloses a process of preparing a nanofiber web by organically combining a flash spinning method and an electrostatic spinning method.
- KR patent publications Nos. 2003-0077384 and 2004-0040692 disclose a method of producing a superfine nanofiber web which is improved in productivity and yield by combination of the melt-blown spinning method and the electrostatic spinning method.
- the present invention has been made to solve the foregoing problems of the prior art and therefore an aspect of the present invention is to provide a dissolvable nano web porous film that is biologically and physiologically applicable.
- Another aspect of the invention is to provide a dissolvable nano web porous film that is quickly dissolved in saliva in administration into the oval cavity or fluid secreted from the skin.
- a further aspect of the present invention is to provide an edible nano web porous film, of which active component is absorbed into the body and which is edible without water.
- Yet another aspect of the present invention is to provide a nano web porous film that has superior dissolvability, drying resistance, and sticking resistance.
- Yet another aspect of the present invention is to provide a dissolvable nano web porous film where an active component and the film are capable of being rapidly decomposed or dissolved.
- Yet another aspect of the present invention is to provide a method of preparing a dissolvable nano web porous film having the foregoing properties.
- the present invention provides a dissolvable nano web porous film having a network structure, wherein the network structure is formed by stacking nano fibers, the nano fibers having a thickness of 10-50,000 nm and formed of a composition composed of (A) a nano fiber forming polymer, (B) a gelling agent, and (C) a plasticizer.
- the present invention provides a method of preparing a dissolvable nano web film, comprising: (1) forming a polymer melt or solution of a composition composed of (A) a nano fiber forming polymer, (B) a gelling agent and (C) a plasticizer, as essential ingredients, and (D) active components, and (E) a ⁇ tives, as optional ingredients; (2) spinning the melt or solution to form a nano web porous film having nano webs stacked in a three-dimensional network structure; (3) drying the nano web porous film; and (4) stabilizing the nano web porous film.
- the dissolvable nano web porous film has a 5-5000 times lager specific surface area and a 2-20 times faster dissolving time than a conventional film.
- the dissolvable nano web porous film is excellent in dissolvability and solubility.
- the dissolvable nano porous film is used for a medicine to be edible without water.
- the film is rapidly dissolvable and liquefied by saliva in the oral cavity, the medicine is absorbed into the bloodstream through a mucous membrane in the oral cavity without any displeasure.
- the medicine is absorbed into the bloodstream without passing through the stomach and gullet, it is advantageous in rapidly providing therapeutic effects.
- the dissolvable nano porous film according to the present invention can be preferably used as a carrier for functional foods, drugs, plant extracts, etc. which have a very small quantity of effective ingredients.
- the dissolvable nano web porous film is provided along with emulsified fat- soluble flavors and emulsified oils and fats to be used as a mouth-freshening nano web porous film or a flavor nano web porous film for bad breath prevention, refreshment, improvement of edibility, nutrients supplementation, drug delivery, improvement of health, etc.
- these films can be a substitute for gum, candies, a spray type oral cleansing agent, a breath freshening agent, and the like.
- the dissolvable nano web porous film is dissolved by fluid secreted from the skin or moisture to be rapidly soluble and liquefied, medicines or functional materials are absorbed epidermally and percu- taneously without displeasure. Accordingly, therapeutic effects are quickly exhibited, and thus the film can be useful for skin care, therapy for skin, etc.
- the dissolvable nano web porous film is provided along with a bleaching agent or a dental bleaching agent to be used as a dental bleaching film.
- Fig. 1 is a mimetic diagram of a portion of a network structure on the surface of a dissolvable nano web porous film according to an exemplary embodiment of the present invention, in which reference numeral 1 indicates a cross section of a nano fiber in the dissolvable nano web porous film, and reference numeral 2 indicates a pore between the nano fibers;
- FIG. 2 is a micrograph of the surface of the nano web porous film taken by a scanning electron microscope (SEM) according to a first exemplary embodiment of the present invention, illustrating that plural nano fibers are stacked to form a nano web where a network structure and pores exist;
- Fig. 3 is an enlarged SEM image of a portion of the surface of the dissolvable nano web porous film according to the first exemplary embodiment of the present invention;
- Fig. 4 is a highly enlarged SEM image of a portion of the surface of the dissolvable nano web porous film according to the first exemplary embodiment of the present invention
- Fig. 5 is an SEM image of the cross section of the dissolvable nano web porous film according to the first exemplary embodiment of the present invention.
- Fig. 6 is an SEM image of the surface of a nonporous film according to a second exemplary embodiment of the present invention.
- Fig. 7 is an SEM image of the cross section of the nonporous film according to the second exemplary embodiment of the present invention.
- Fig. 8 is a graph illustrating the relation (i.e., dissolvability in tepid water and in the oral cavity) between the dissolving time and the thickness of the dissolvable nano web porous film according to the first exemplary embodiment of the present invention and the relation between the dissolving time and the thickness of the nonporous film according to the second exemplary embodiment of the present invention.
- the present invention relates to a dissolvable nano web porous film that can be rapidly dissolved by saliva in the oral cavity or fluid secreted from the skin, and a method of preparing the same.
- the nano web porous film has a large surface area, pores and a rapidly soluble network structure capable of rapidly responding to materials from the outside, and is rapidly dissolved by the saliva in the oral cavity or the fluid secreted from the skin. Due to the film's rapid dissolvability, active components (e.g., drugs and the like) in the film can be more effectively absorbed into the body. Also, the film has edibility to allow the film to be edible without water and without any displeasure in a dissolved state, dissolvability, drying resistance, and sticking resistance.
- the dissolvable nano web porous film according to the exemplary embodiment of the present invention has a network structure where nano fibers having a thickness of 10-50,000 nm are stacked.
- the nano fibers are formed of a composition composed of (A) a nano fiber forming polymer, (B) a gelling agent, and (C) a plasticizer. If the nano fiber has a thickness less than 10 nm, it is difficult to me- chanically produce the film. If the nano fiber has a thickness more than 50,000 nm, the film has reduced dissolvability.
- the nano web porous film is preferably formed to have a thickness of 5-500 ⁇ m to obtain excellent properties in view of drying resistance, feeling in the oral cavity, dissolvability in the oral cavity, etc.
- the nano web porous film preferably has porosity ranging from 10-90%. If the porosity is less than 10%, it is difficult to mechanically produce the film. If the porosity is more than 90%, it is difficult to form a nano web.
- the nano web porous film preferably has a specific surface area in the range of 1-1,000 mVg. If the specific surface area is less than 1 mVg, the film may not exhibit excellent dissolvability. If the specific surface area is more than 1,000 mVg, it is difficult to mechanically produce the film.
- the dissolvable nano web porous film [50] According to the present invention, the dissolvable nano web porous film
- nano fibers having a composition that essentially consist of (A) a nano fiber forming polymer, (B) a gelling agent, and (C) a plasticizer.
- the composition, which forms the nano fiber may further comprise (D) an active component andhr (E) other a ⁇ tives according to use of the porous film, if necessary.
- the nano fiber forming polymer (A) an ingredient of the composition for forming the (dissolvable and/ ⁇ r edible) nano web porous film, is a main ingredient for the nano fiber and the nano web porous film, and carries active components in a nano web.
- nano fiber forming polymer (A) used to form the film of the invention examples include, but are not limited to, pullulan, hjdroxypropylmethyl cellulose (HPMC), hylroxymethyl cellulose (HMC), hylroxyethyl cellulose (HEC), hy- droxypropyl cellulose (HPC), ethyl cellulose (EC), methyl cellulose (MC), hjdrox- ypropylmethyl cellulose phthalate (HPMCP), hyiroxypropylmethyl cellulose acetate succinate (HPMCAS), cellulose acetate phthalate (CAP), carboxymethyl cellulose (CMC), polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), sodium alginate, polyethylene glycol, locust bean gum, xanthan gum, tragacanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, methyl methacryl
- the nano fiber forming polymer (A) has an average molecular weight of 1,000-2,000,000 g/mol. If the average molecular weight is less than 1,000 g/mol, the viscosity of the polymer is low, making it difficult to form a nano web. If the average molecular weight is more than 2,000,000 g/mol, the viscosity is high, making it difficult to process the polymer. In addition to the aforementioned polymers, any of known hydrophilic natural polymers having an average molecular weight of 1,000-2,000,000 g/mol may be used to form the film of the invention.
- the nano fiber forming polymer (A) is added in an amount of l ⁇ 99wt%, and preferably, of about 15 ⁇ 80wt%, to the composition of the nano web porous film. If the polymer content is less than lwt%, it is difficult to form a fiber. And, since other solvents or ingredients should also be mixed in formation of the nano fiber, the polymer content may be added up to 99wt%.
- composition [55] The other ingredients (specifically, the gelling agent, plasticizer, active ingredients, additives, and water) of the composition are added to the composition according to proposed contents and conditions, which will be described below.
- the gelling agent an ingredient of the composition to form the dissolvable nano web porous film, is used to prevent the nano web porous film from breaking, and becomes gel when cooled.
- the gelling agent include, but are not limited to, a natural gelling agent, such as locust bean gum, xanthan gum, carrageenan, gelatin, gellan gum, agar, alginates, guar gum, starch, pectin, ethyl cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyethylene glycol, and combinations thereof. Also, a mixture of two or more aforementioned materials may be used as the gelling agent.
- a mixing ratio of the gelling agent (B) to 100wt% polymer (A) is in the range of about 0.1 ⁇ 50wt% (for example, 0.1-50 parts by weight gelling agent to 100 parts by weight polymer), and preferably, of 0.4 ⁇ 30wt%. If the mixing ratio is below the range, the film tends to be curled. Conversely, if the ratio exceeds the range, the film has low dissolvability.
- the plasticizer is used to endow the film with properties of hardening prevention, sticking prevention, and plasticity.
- the plasticizer also drops the glass transition temperature of the film during the process, thereby adjusting the melting viscosity thereof.
- the plasticizer includes, but are not limited to, sorbitol, mannitol, glycerin, propylene glycol, polyethylene glycol, fatty acid glycerol monoester, sugar alcohol, monosaccharide, oligosaccharide, Methylene glycol, myvacet, triethyl citrate, triacetin, propylene glycol monocaprylate, propylene glycol dicaprylate, miglyol, etc., all of which are organic compounds of polyol containing at least one hjdroxyl group.
- alcohol-based or polyol-based organic compounds induing at least one hjdroxyl group may be used as the plasticizer. These materials are used independently or together. A mixture of two or more aforementioned materials may be used as the plasticizer.
- a mixing ratio of the plasticizer (C) to 100wt% polymer (A) is in the range of about 0.1 ⁇ 40wt% (for example, about 0.1- 40 parts by weight plasticizer to 100 parts by weight polymer). If the mixing ratio is below the range, the film deteriorates in drying resistance. If the ratio is above the range, the film deteriorates in sticking resistance.
- the composition may further comprise an active component as necessary.
- the active component comprises food, medicines, drugs, functional materials, etc., which promote structural and functional modifications in the body to which it is administered.
- the active component is not specifically limited, but provided as any of materials which are physiologically applicable, mixable with other materials of the nano web porous film, and have activity corresponding to uses of the film.
- the active component include, but are not limited to, one selected from the group or type consisting of: ⁇ -adrenergic agonists; ⁇ -adrenergic agonists; ⁇ -adrenergic blocking agents; ⁇ -adrenergic blocking agents; alcohol prohibition agents; aldose-reductase inhibitors; anabolic agents; narcotic analgesics; derivatives of morphine; non-narcotic analgesics, preferably, salicylates and derivatives thereof; androgens; anesthetics; appetite inhibitors; anthelmintics (taenia, nematode, filarial, schistosome, and fluke eliminating active agents); antiacne agents; antiallergic agents; antiamebic drugs (ameba eliminating agents); antiandrogens
- the active component is an optional ingredient and selectively added according to purposes of the nano web porous film.
- the active component is not limited to the aforementioned materials, but may employ drugs which can be pharmaceutically activated.
- the active component is not specifically limited to a certain component, so long as it is capable of being dissolved in water or ethanol. A proper dosage of the active component is 0.001-50 mg.
- the dissolvable nano web porous film is edible without water, and rapidly dissolved and liquefied by saliva in the oral cavity, so that drugs may be absorbed into the body without any displeasure. Even in this case, it is desirable to use an active component (drugs and the like) which does not have ill-affect on digestive organs, the mucous membrane in the oral cavity, and the like.
- the active component is optionally provided up to 40wt%, and preferably, 0.01 ⁇ 40wt%, with respect to the total weight of the final film.
- the active component does not have any lower limit in content, but can be added in a content of 0.01wt% or more with respect to the final film so as to exhibit its properties by the addition. If the content of the active component exceeds 40wt%, it is difficult to form a nano web.
- additives may be optionally added to the composition for the dissolvable nano web porous film to improve properties required for the film.
- the additives include, but are not limited to, flavoring agents, sulfur precipitating agents, saliva stimulating agents, cooling agents, surfactants, stabilizing agents, emulsifying agents, thickening agents, binding agents, coloring agents, pigments, sweeteners, fragrances, germicides, antimicrobial agents, pharmaceutical active agents, etc.
- the additives may be provided as, but are not limited to, saccharides to improve taste (all typical saccharides, for example, but not limited to, white sucrose, maltose, fructose, galactooligosaccharide, galactose, fructooligosaccharide, dextrin, ion starch syrup, malt syrup, lactose, glucose, sorbitol, mannitol, xylitol, inositol, etc.); saliva stimulating agents (e.g., but not limited to, citric, lactic, maleic, succinic, ascorbic, adipic, fumaric, and tartaric acids); sweeteners (e.g., but not limited to, monosaccharide, disaccharide, ribose, glucose, mannose, galactose, fructose, sucrose, maltose, invert sugars, corn syrup solids, glythyl retinoate
- the additives are provided up to 40wt%, and preferably, in the range of
- the additives do not have a lower limit in content, but should be added in a content of 0.01wt% or more with respect to the final film so as to exhibit its properties by the addition. If the content of additives exceeds 40wt%, it is difficult to form a nano web.
- composition is melted or dissolved to form a polymer melt or polymer solution.
- the polymer melt or solution is spun into nano fibers, and the fibers are stacked, thereby producing a nano web porous film in a network structure according to the present invention.
- the method of preparing the nano web porous film according to the present invention will be described in detail.
- a composition which comprises (A) a nano fiber forming polymer, (B) a gelling agent, and (C) a plasticizer, as essential ingredients, and (D) an active component and/ or (E) additives, as optional ingredients, is melted or dissolved to prepare a polymer melt or polymer solution.
- (A) to (E) ingredients may be added regardless of order, which is adjusted by those skilled in the art in consideration of properties and characteristics thereof.
- a single or two or more ingredients may be melted or dissolved according to proper selection by those skilled in the art in consideration of the properties and characteristic thereof.
- a polymer solution can be produced by the following process: dissolving or dispersing (A) a nano web film forming polymer in a solvent in an amount of about 1.5-4.5 times the total amount of the polymer at room temperature or a certain temperature, adding (B) a gelling agent and (C) a plasticizer thereto, followed by dissolving them, and dissolving and dispersing (D) an active component and (E) additives as necessary.
- water is generally used as a solvent.
- the polymer melt or polymer solution is spun into nano fibers.
- the spinning process is performed by, for example, spun-lace, spun-bond, melt-blown, flash spinning, electro spinning, etc.
- the nano fibers are formed in the form of non- woven fabrics by spinning the polymer melt or polymer solution.
- a nano web is produced in a network structure where a great number of nano fibers are stacked.
- the nano fibers are stacked or wound evenly such that the nano web has a uniform overall thickness.
- the nano web having the network structure where the plural nano fibers are stacked or wound evenly can be used as a porous film of the present invention.
- a solid content of the polymer melt or polymer solution is preferably adjusted to a concentration of about 15 ⁇ 50wt%. If the solid content is less than 15wt%, it is difficult to form a nano web due to low viscosity. If the solid content is more than 50wt%, it is difficult to form a stream of polymer melt or polymer solution using electric force due to high viscosity.
- the spinning process is performed, but is not limited to, as follows.
- the polymer melt or polymer solution is stored in a syringe, and is pressurized at a constant pressure by means of a syringe pump. Then, the pressurized polymer melt or solution in a liquid phase is pushed out through a minute opening (an inner diameter of 0.1-2 mm) of a nozzle tip in a spinning unit via an inlet pipe.
- the solvent is volatilized or congeals, and nano fibers are stacked or wound on the surface of a collector (e.g., drum) disposed at a predetermined distance, thereby forming the nano web having the network structure.
- a collector e.g., drum
- the nano web of the network structure it is possible to regulate the porosity of the nano web, the diameter, size and form of the nano fiber, the thickness of the nano web, etc. by controlling some factors (e.g., the diameter of the nozzle tip, the intensity of electric field, the distance between the nozzle tip and the collector, the discharging speed of the melt/solution, the number of nozzles, the discharging amount of the melt/solution, the spinning time, etc.).
- the nano web is spun and stacked to have a thickness of about 5-500 ⁇ m in order that the dissolvable nano web porous film has excellent drying resistance, feeling in the oral cavity, dissolvability in the oral cavity, and other properties.
- a network structure nano web of nano fibers which are formed of different kinds of compositions mixed to exhibit different functions and effects, may be stacked and/ ⁇ r wound to produce a multilayer film that has a variety of properties.
- the nano webs formed of the nano fibers and having the network structure are stacked to form the porous film, while being adjusted in thickness, density, and porosity thereof. If the nano webs are formed desired thick and densely, the nano webs themselves may be used as the nano web porous film without compression process. Optionally, the nano webs of the network structure formed at the process (2) are compressed to a desired thickness, if necessary to produce the nano web porous film.
- the nano web porous film has a thickness of 5-500 ⁇ m, and preferably, of about 10-200 ⁇ m, to obtain excellent properties relating to drying resistance, feeling in the oral cavity, dis solvability in the oral cavity, etc.
- the nano web film formed in a film type is dried by hot air at about 80-110 0 C so as to have a moisture content of 5 ⁇ 20wt%. If the drying temperature is less than 8O 0 C, the solvent is not likely to be volatilized, and the film is not dried rapidly. If the temperature is more than 11O 0 C, the film can be deformed. Also, if the moisture content of the film is less than 5wt%, it can be easily broken, whereas, if the content is more than 20wt%, the film is likely to droop and become sticky.
- the dried nano web porous film is kept in a humidity adjusted space or in a thermo- hygrostat to stabilize the moisture content, and the like.
- the stabilization is performed to allow the nano web porous film to have a moisture content of about 5- 15wt% so as to achieve optimal properties relating to feeling in the oral cavity, preservative performance, etc. If the stabilized final porous film has the content of moisture less than 5wt%, it can be easily broken. If the moisture content of the film is more than 15wt%, it tends to droop, and becomes sticky.
- the stabilization is preferably performed at a temperature of 20 ⁇ 30°C and a relative humidity of 40-50% for 1 to 48 hours in order to achieve optimal properties of the film. It should be noted that the present invention is not limited to the aforementioned stabilization conditions. For example, the stabilization can be generally performed at a temperature of 25 0 C and a relative humidity of 45% for 24 hours.
- Fig. 1 is a mimetic diagram of a portion of the network structure on the surface of the dissolvable nano web porous film according to an exemplary embodiment of the invention.
- Reference numeral 1 indicates a cross section of a nano fiber in the dissolvable nano web porous film
- reference numeral 2 indicates a pore formed between the nano fibers.
- the nano web porous film of the network structure comprises a plurality of nano fibers (1), which have a diameter of several to tens of thousands of nanometers and a plurality of pores (2) formed among the nano fibers, it has very high specific surface area and porosity per weight.
- the porous film of the invention has the nano web structure which is constituted by the network structure and the pores, the porous film has excellent surface activity and dis- solvability.
- the active components drug and the like
- carriers or other additives in the film are rapidly dissolved and/ ⁇ r melted by saliva in the oral cavity or fluid secreted from the skin, so medicines or other active components can be more quickly discharged in the oral cavity or on the skin.
- the porous film exhibits rapid dissolution with a dissolution time in the range of 1-60 seconds, and excellent dis- solvability, which is twice to twenty times higher than that of the conventional nonporous film.
- the dissolvable nano web porous film is decomposed and easily dissolved by reaction with amylase of saliva in the oral cavity.
- the dissolvable nano web porous film exhibits excellent dis solvability and rapid dissolution, particularly in the oral cavity.
- the edible nano web porous film of the invention may be used as a package or carrier to carry functional foods, vitamins, essential minerals, drugs, etc., which can be taken through the oral cavity. Also, since flavoring agents, refined oil, etc. are added to the porous film when it is formed, the porous film can be used as a flavoring carrier. Thus, the film can be used in new forms for health improvement, such as bad breath prevention, refreshment, improvement of edibility, nutrients supplementation, drug delivery, health food supplement, etc.
- the dissolvable nano web porous film is produced including active components such as drugs, it can be formed as an edible material, which is edible without water.
- the porous film exhibits edibility to be rapidly dissolved and liquefied by saliva in the oral cavity, so that medicines can be absorbed in the body without any displeasure.
- the porous film is excellent in view of dissolvability, drying resistance, and sticking resistance, which are fundamental properties required for a dissolvable film.
- the porous film is biologically and physiologically applicable. That is, the porous film has a solubility that is physiologically allowable in the skin and mucous membranes such as the oral cavity, the gullet, etc.
- the conventional nonporous film should have a certain thickness to perform intended functions, e.g., to load active components.
- the thickness of the film must be determined by the properties and amount of the active components to be discharged from the film.
- an increase in thickness of the film leads to a decrease in decomposition and dissolution rates of the nonporous film.
- not only a thin nonporous film but also a thick nonporous film tends to stick to the palate or other portions of the mucous membrane in the oral cavity due to its nonporous smooth surface and extended decomposition. This is because the surface of polymer layers is dissolved into a sticky film.
- the dissolvable nano web porous film of the invention can be formed in a variety of thickness as necessary. Accordingly, unlike the conventional nonporous film, the nonporous film of the invention is not only prevented from sticking to the surface of the oral cavity, but also rapidly delivers materials due to its wide specific surface area when applied to the mucous membrane of the oral cavity. Thus, the nonporous film has improved discharging effect to discharge medicines fast, and has excellent solubility and dissolvability. Mode for the Invention
- the polymer solution prepared at process (1) was stored in a syringe, and supplied to an inlet pipe by a syringe pump at a constant speed of 45 ⁇ Jllh.
- the solution in a liquid phase was pushed out through a minute opening (an inner diameter of 0.2 mm) of a nozzle tip in a spinning unit via the inlet pipe.
- nano fibers were stacked and wound on the surface of a collector disposed at a predetermined distance while the solvent is volatized or congealed, forming a nano web having a three-dimensional network structure.
- the nano web of the three-dimensional network structure was compressed at a pressure of 2 atm to form a film having a two-dimensional plate structure.
- the nano web was compressed to form a nano web porous film having a thickness of 10-50 ⁇ m.
- the nano web porous film formed at process (2)-l was dried by air heated to about 80-11O 0 C for one minute to adjust its moisture content to 5 ⁇ 20wt%.
- the nano web porous film dried at process (4) was kept in a thermo-hygrostat at a temperature of 25 0 C and a relative humidity of 45% for 24 hours to be stabilized. Then, the nano web porous film had a moisture content of about 1 l ⁇ 13wt%.
- the dissolvable nano web porous film was cut into pieces 2 cm wide by 3 cm long. With a piece as a sample, the nano web porous film of 10-50 ⁇ m in thickness was evaluated with respect to its film forming properties and dissolvability. The film forming properties and dissolvability were evaluated by the following method.
- the sample film was examined using an electron microscope to obtain its forming state, size of the nano fiber, network structure, etc. Results are shown in Figs. 2 to 5.
- the specific surface area of the dissolvable nano web porous film was measured by the BET (Brunauer, Emmett, Teller) method.
- the nano fiber had a diameter of about 200 nm
- the porous film had a specific surface area of 110 mVg and porosity of 42%.
- the sample film was put in tepid water at 35 0 C, and left after being shaken two or three times. Here, the container was carefully shaken such that the film was not stuck on the wall of the container. Then, the dissolvability of the film was evaluated by measuring time taken for complete dissolution of the film.
- the dissolvability of the film in the oral cavity was determined by putting the sample film in the mouth of an adult male and measuring time taken for complete dissolution of the film by saliva. Results of the dissolvability in tepid water and in the oral cavity are shown in Fig. 8.
- the porous film having a thickness of 20 ⁇ m in this example was completely dissolved within 7 seconds in tepid water and within 8 seconds in the oral cavity.
- the solution was kept for 6 hours or more to remove air bubbles. Then, the solution was coated to a thin film and cast to produce a film having a thickness in the range of 10-50/M.
- the resulting nonporous film was dried by heated air at about 60- 100 0 C and kept in a thermo-hygrostat at a temperature of 25 0 C and a relative humidity of 45% for 24 hours to be stabilized.
- the nonporous film had a moisture content of about 1 l ⁇ 13wt%.
- the nonporous film was cut into pieces 2 cm wide by 3 cm long.
- the nonporous film produced in this example was evaluated by the same method as in Example 1 with respect to film forming properties and dissolvability (evaluation of surface-active reaction of nonporous film).
- a film-forming state of the film was observed by an electron microscope, of which results are shown in Figs. 6 and 7.
- Results of the dissolvability in tepid water and in the oral cavity are shown in Fig. 8.
- the nonporous film having a thickness of 20 ⁇ m was completely dissolved within 33 seconds in tepid water and within 35 seconds in the oral cavity.
- sucrose fatty acid ester was added to 71.41wt% distilled water, and sufficiently uniformly dispersed at room temperature. Then, 0.3wt% sorbitol, 0.9wt% propylene glycol and 0.4wt% glycerine were added to the resulting solution, and heated to 7O 0 C. 23wt% hydroxypropylmethyl cellulose (HPMC) was slowly added to the heated solution, and stirred to be completely dissolved in the solution.
- HPMC hydroxypropylmethyl cellulose
- Example 4 After heating 77wt% distilled water to 7O 0 C, 21wt% pectin, 0.5wt% carrageenan,
- solutions were prepared using ingredients and content shown in Table 1 by the following process. Avicel was added to distilled water (DW), and sufficiently uniformly dispersed at room temperature for about 10 minutes. Also, sucrose fatty acid ester was added to the solution, and completely dissolved therein. (In Examples 10, 16 and 22 where avicel was not used, sucrose fatty acid ester was added to distilled water, and sufficiently dissolved at room temperature for about 10 minutes.) Then, sorbitol, propylene glycol, and glycerine were added to the resulting solution and heated to 7O 0 C. Pullulan, pectin, and hydroxypropylmethyl cellulose (HPMC) were slowly added to the heated solution, and stirred to be completely dissolved in the solution.
- HPMC hydroxypropylmethyl cellulose
- Examples 41 to 4% solutions were prepared using ingredients shown in Table 3 by the following process. Sucrose fatty acid ester was added to distilled water heated to 5O 0 C, and completely dissolved. Then, propylene glycol and glycerine were added to the resulting solution, and slowly heated to 7O 0 C. Pullulan was slowly added to the heated solution, stirred to be completely dissolved in the solution. After heating the resulting solution to 8O 0 C, carrageenan, locust bean gum (LBG), and xanthan gum were added to the heated resulting solution, and completely dispersed and dissolved.
- LBG locust bean gum
- xanthan gum were added to the heated resulting solution, and completely dispersed and dissolved.
- a pharmaceutical active agent e.g., dextromethorphan HBr in Example 41, phenylephrine HCl in Example 42, alkylamines chloropheniramine in Example 43, loperamide HCl in Example 44, Nicotine for Example 45, magnesium stearate in Example 46, oxybutynin in Example 47, and extradiol in Example 48
- the solution was stirred until all ingredients were uniformly dispersed and completely dissolved, thereby preparing a polymer solution.
- a nano web porous film was produced using the solution by the same method as in Example 1, and cut in pieces of a suitable size capable of ensuring a suitable pharmaceutical content, thereby preparing a pharmaceutical nano web porous film.
- solutions were prepared using ingredients in Table 4 by the following process. Avicel was added to distilled water (DW), and sufficiently uniformly dispersed at room temperature for about 10 minutes. Also, sucrose fatty acid ester and polysorbate 80 were added to the solution, and completely dissolved therein. Then, sorbitol, propylene glycol, and glycerine were added to the resulting solution and heated to 7O 0 C. Pullulan, pectin and hydroxypropylmethyl cellulose (HPMC) were slowly added to the heated solution, and stirred to be completely dissolved in the solution.
- DW distilled water
- HPMC hydroxypropylmethyl cellulose
- Examples 67 to 72 solutions were prepared using ingredients shown in Table 5 by the following process. Avicel was added to distilled water (DW), and sufficiently uniformly dispersed at room temperature for about 10 minutes. Also, sucrose fatty acid ester and polysorbate 80 were added to the solution, and completely dissolved therein. Then, sorbitol, propylene glycol, and glycerine were added to the resulting solution and heated to 7O 0 C. Pullulan was slowly added to the heated solution, and stirred to be completely dissolved in the solution. After heating the resulting solution to 8O 0 C, carrageenan, locust bean gum (LBG), xanthan gum and guar gum are added thereto, and completely dispersed and dissolved.
- LBG locust bean gum
- xanthan gum and guar gum are added thereto, and completely dispersed and dissolved.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07808135.3A EP2187970A4 (en) | 2007-08-10 | 2007-09-07 | Dissolvable nano web porous film and method of preparing the same |
CN2007801007557A CN102014962B (en) | 2007-08-10 | 2007-09-07 | Dissolvable nano web porous film and method of preparing the same |
US12/672,950 US20110250256A1 (en) | 2007-08-10 | 2007-09-07 | Dissolvable Nano Web Porous Film and Method of Preparing the Same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2007-0080677 | 2007-08-10 | ||
KR20070080677A KR100937625B1 (en) | 2007-08-10 | 2007-08-10 | Dissolvable Web Porous Film and Preparing Method Thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009022761A1 true WO2009022761A1 (en) | 2009-02-19 |
Family
ID=40350806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2007/004342 WO2009022761A1 (en) | 2007-08-10 | 2007-09-07 | Dissolvable nano web porous film and method of preparing the same |
Country Status (5)
Country | Link |
---|---|
US (1) | US20110250256A1 (en) |
EP (1) | EP2187970A4 (en) |
KR (1) | KR100937625B1 (en) |
CN (1) | CN102014962B (en) |
WO (1) | WO2009022761A1 (en) |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012003350A1 (en) * | 2010-07-02 | 2012-01-05 | The Procter & Gamble Company | Methods of delivering a health care active by administering personal health care articles comprising a filament |
WO2012003365A1 (en) * | 2010-07-02 | 2012-01-05 | The Procter & Gamble Company | Filaments comprising an ingestible active agent nonwoven webs and methods for making same |
WO2012003300A3 (en) * | 2010-07-02 | 2012-02-16 | The Procter & Gamble Company | Filaments comprising a non-perfume active agent nonwoven webs and methods for making same |
WO2012003319A3 (en) * | 2010-07-02 | 2012-02-23 | The Procter & Gamble Company | Filaments comprising an active agent nonwoven webs and methods for making same |
WO2012003367A3 (en) * | 2010-07-02 | 2012-03-01 | The Procter & Gamble Company | Method for delivering an active agent |
WO2012003351A3 (en) * | 2010-07-02 | 2012-05-10 | The Procter & Gamble Company | Web material and method for making same |
WO2012097763A2 (en) * | 2011-01-17 | 2012-07-26 | Elmarco S.R.O. | A carrier for oromucosal, especially sublingual administration of physiologically active substances |
WO2012125297A1 (en) * | 2011-03-01 | 2012-09-20 | The Procter & Gamble Company | Porous disintegratable solid substrate for personal health care applications |
CN102959148A (en) * | 2010-06-29 | 2013-03-06 | 花王株式会社 | Nanofibre laminate sheet |
WO2013035072A1 (en) * | 2011-09-08 | 2013-03-14 | Vile Glenn | Bioactive nanofibres |
JP2013509495A (en) * | 2010-07-02 | 2013-03-14 | ザ プロクター アンド ギャンブル カンパニー | Method for making a film from a nonwoven web |
CN102985603A (en) * | 2010-07-02 | 2013-03-20 | 宝洁公司 | Filaments comprising an active agent nonwoven webs and methods for making same |
WO2012003349A3 (en) * | 2010-07-02 | 2013-04-18 | The Procter & Gamble Company | Dissolvable fibrous web structure article comprising active agents |
US9018193B2 (en) | 2010-09-13 | 2015-04-28 | Bev-Rx, Inc. | Aqueous drug delivery system |
EP2765160A4 (en) * | 2011-10-04 | 2015-06-17 | Genic Co Ltd | Hydrogel composition for a mask base and method for manufacturing a hydrogel using same |
CN105727358A (en) * | 2016-02-23 | 2016-07-06 | 广西易得佳医疗器械有限公司 | Drug-loaded biopolymer compound nanofiber membrane and preparation method thereof |
CN107177049A (en) * | 2017-05-23 | 2017-09-19 | 佛山市因诺维生物科技有限公司 | A kind of HPG nano cellulose composite film and preparation method thereof |
US9827173B2 (en) | 2014-05-05 | 2017-11-28 | The Procter & Gamble Company | Porous dissolvable solid structure with two benefit agents and methods of forming an aqueous treatment liquor therefrom |
WO2018005571A1 (en) | 2016-06-30 | 2018-01-04 | The Gillette Company Llc | Shaving aid for razor cartridges comprising a nano-filament comprisng a core and sheath |
WO2018005574A1 (en) | 2016-06-30 | 2018-01-04 | The Gillette Company Llc | Shaving aid for razor cartridges comprising a nano-filament |
WO2018005148A1 (en) | 2016-06-30 | 2018-01-04 | The Gillette Company Llc | Shaving aid for razor cartridges comprising filaments |
US9861558B2 (en) | 2014-05-05 | 2018-01-09 | The Procter & Gamble Company | Methods of forming an aqueous treatment liquor by dissolving a porous solid with a benefit agent coating |
US9861559B2 (en) | 2014-05-05 | 2018-01-09 | The Procter & Gamble Company | Consumer product comprising a porous, dissolvable, fibrous web solid structure with a silicone coating |
US9867762B2 (en) | 2014-05-05 | 2018-01-16 | The Procter & Gamble Company | Consumer product comprising a porous dissolvable solid structure and silicone conditioning agent coating |
US9877899B2 (en) | 2014-05-05 | 2018-01-30 | The Procter & Gamble Company | Consumer product comprising a fibrous web structure with a silicone conditioning agent coating |
US9937111B2 (en) | 2014-05-05 | 2018-04-10 | The Procter & Gamble Company | Consumer product comprising a fibrous web solid structure with a silicone conditioning agent coating |
CN109966540A (en) * | 2019-04-04 | 2019-07-05 | 武汉大学 | A kind of preparation method and application of nano-chitosan compound calcium alginate medical dressing |
WO2019222125A1 (en) * | 2018-05-14 | 2019-11-21 | The Procter & Gamble Company | Unit-dose oral care compositions |
US10982176B2 (en) | 2018-07-27 | 2021-04-20 | The Procter & Gamble Company | Process of laundering fabrics using a water-soluble unit dose article |
US11053466B2 (en) | 2018-01-26 | 2021-07-06 | The Procter & Gamble Company | Water-soluble unit dose articles comprising perfume |
US11142730B2 (en) | 2018-01-26 | 2021-10-12 | The Procter & Gamble Company | Water-soluble articles and related processes |
US11193097B2 (en) | 2018-01-26 | 2021-12-07 | The Procter & Gamble Company | Water-soluble unit dose articles comprising enzyme |
RU2782456C2 (en) * | 2016-12-23 | 2022-10-27 | Контипро A.С. | Ophthalmic preparation |
US11505379B2 (en) | 2018-02-27 | 2022-11-22 | The Procter & Gamble Company | Consumer product comprising a flat package containing unit dose articles |
US11679066B2 (en) | 2019-06-28 | 2023-06-20 | The Procter & Gamble Company | Dissolvable solid fibrous articles containing anionic surfactants |
IT202200004418A1 (en) * | 2022-03-08 | 2023-09-08 | Bakel S R L | COMPOSITION TO BE ELECTROWIRED |
US11753608B2 (en) | 2018-01-26 | 2023-09-12 | The Procter & Gamble Company | Water-soluble unit dose articles comprising perfume |
US11859338B2 (en) | 2019-01-28 | 2024-01-02 | The Procter & Gamble Company | Recyclable, renewable, or biodegradable package |
US11878077B2 (en) | 2019-03-19 | 2024-01-23 | The Procter & Gamble Company | Fibrous water-soluble unit dose articles comprising water-soluble fibrous structures |
US11911492B2 (en) | 2018-05-14 | 2024-02-27 | The Procter & Gamble Company | Oral care compositions comprising metal ions |
US11925698B2 (en) | 2020-07-31 | 2024-03-12 | The Procter & Gamble Company | Water-soluble fibrous pouch containing prills for hair care |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8765170B2 (en) | 2008-01-30 | 2014-07-01 | The Procter & Gamble Company | Personal care composition in the form of an article |
MX2010011378A (en) | 2008-04-16 | 2010-11-12 | Procter & Gamble | Non-lathering personal care composition in the form of an article. |
CA2723307C (en) * | 2008-05-05 | 2017-08-22 | Euro-Celtique S.A. | Tamper resistant opioid composition for treating skin lesions |
MX339322B (en) | 2009-12-08 | 2016-05-20 | Procter & Gamble | A porous, dissolvable solid substrate and surface resident coating comprising matrix microspheres. |
WO2011103152A1 (en) | 2010-02-16 | 2011-08-25 | The Procter & Gamble Company | A porous, dissolvable solid substrate and surface resident coating comprising a zync pyrithione |
US20180163325A1 (en) | 2016-12-09 | 2018-06-14 | Robert Wayne Glenn, Jr. | Dissolvable fibrous web structure article comprising active agents |
US20140378661A1 (en) * | 2011-04-20 | 2014-12-25 | Trustees Of Tufts College | Molded regenerated silk geometries using temperature control and mechanical processing |
US8939957B2 (en) | 2011-04-29 | 2015-01-27 | The Procter & Gamble Company | Absorbent article with leg gasketing cuff |
JP2014516758A (en) | 2011-06-21 | 2014-07-17 | ザ プロクター アンド ギャンブル カンパニー | Absorbent article with gathered waistband and leg cuff |
WO2012177400A1 (en) | 2011-06-21 | 2012-12-27 | The Procter & Gamble Company | Absorbent article with waistband having contraction |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
ES2885523T3 (en) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Natural combination hormone replacement formulations and therapies |
JP5964453B2 (en) * | 2012-01-04 | 2016-08-03 | ザ プロクター アンド ギャンブル カンパニー | Active substance-containing fibrous structure having a plurality of regions having different densities |
US9139802B2 (en) * | 2012-01-04 | 2015-09-22 | The Procter & Gamble Company | Active containing fibrous structures with multiple regions |
EP2849702A1 (en) | 2012-05-15 | 2015-03-25 | The Procter & Gamble Company | Disposable absorbent pants with advantageous stretch and manufacturability features, and methods for manufacturing the same |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
MX370280B (en) | 2012-10-12 | 2019-12-09 | Procter & Gamble | Personal care composition in the form of a dissolvable article. |
CN102943318A (en) * | 2012-11-28 | 2013-02-27 | 苏州大学 | polyvinyl alcohol (PVA)/sodium carboxy methylated cellulose (Na-CMC) nanofiber, preparation method and application |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
KR101407922B1 (en) | 2013-11-14 | 2014-06-17 | 주식회사 서울제약 | Porous Orally Disintegrating Film comprising pharmacologically active substance and Precess For Producing thereof |
US20150132575A1 (en) * | 2013-11-14 | 2015-05-14 | Honeywell International Inc. | Luminescent fibers, articles including the same, and methods of forming the same |
US20150315350A1 (en) | 2014-04-22 | 2015-11-05 | The Procter & Gamble Company | Compositions in the Form of Dissolvable Solid Structures |
EP3134564B1 (en) * | 2014-04-22 | 2018-06-20 | The Procter and Gamble Company | Filaments and fibrous structures employing same |
GB2535666B (en) | 2014-04-30 | 2017-03-29 | Matoke Holdings Ltd | Antimicrobial compositions |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
CN107106720B (en) * | 2014-06-05 | 2020-06-16 | 约翰内斯堡威特沃特斯兰德大学 | Wound dressing |
CA2977387C (en) * | 2015-03-04 | 2020-04-28 | The Procter & Gamble Company | Fibrous elements, fibrous structures, and products comprising a deterrent agent and methods for making same |
CN107427396A (en) | 2015-03-18 | 2017-12-01 | 宝洁公司 | Absorbent article with leg cuff |
EP3270852B1 (en) | 2015-03-18 | 2019-08-21 | The Procter and Gamble Company | Absorbent article with waist gasketing element and leg cuffs |
EP3270855B1 (en) | 2015-03-18 | 2020-02-26 | The Procter and Gamble Company | Absorbent article with leg cuffs |
US10524963B2 (en) | 2015-03-18 | 2020-01-07 | The Procter & Gamble Company | Absorbent article with waist gasketing element and leg cuffs |
WO2016149589A1 (en) | 2015-03-18 | 2016-09-22 | The Procter & Gamble Company | Absorbent article with leg cuffs |
US10524962B2 (en) | 2015-03-18 | 2020-01-07 | The Procter & Gamble Company | Absorbent article with waist gasketing element and leg cuffs |
JP6518783B2 (en) | 2015-03-18 | 2019-05-22 | ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company | Absorbent article comprising a waist gasket element and a leg cuff |
US10716716B2 (en) | 2015-03-18 | 2020-07-21 | The Procter & Gamble Company | Absorbent article with leg cuffs |
WO2016149593A1 (en) | 2015-03-18 | 2016-09-22 | The Procter & Gamble Company | Absorbent article with waist gasketing element and leg cuffs |
JP2018512917A (en) | 2015-03-18 | 2018-05-24 | ザ プロクター アンド ギャンブル カンパニー | Absorbent article with leg cuff |
KR101692515B1 (en) * | 2015-04-06 | 2017-01-03 | 동국대학교 산학협력단 | Biodegradable Ultraviolet Light Screening Packaging Film Comprising Biopolymers and Grapefruit Seed Extract, and Manufacturing Method Thereof |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
CN105039139B (en) * | 2015-09-16 | 2017-11-21 | 烟台森森环保科技有限公司 | A kind of microculture film and microculture recovery system |
CN105663025A (en) * | 2016-02-29 | 2016-06-15 | 浙江工业大学 | Drug-containing microfilament and preparation method thereof |
WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
CN106436021A (en) * | 2016-11-18 | 2017-02-22 | 天津捷盛东辉保鲜科技有限公司 | Edible food fresh keeping electrospinning fiber membrane |
CA3046725A1 (en) | 2017-01-11 | 2018-07-19 | Ferring B.V. | A fast disintegrating pharmaceutical composition |
JP7074970B2 (en) | 2017-01-13 | 2022-05-25 | ルナ ラブズ ユーエスエー, エルエルシー | Specimen recovery kit containing soluble nanofiber material and the same material for high efficiency sample recovery |
MX2019008761A (en) | 2017-01-27 | 2019-09-18 | Procter & Gamble | Compositions in the form of dissolvable solid structures comprising effervescent agglomerated particles. |
EP3573593B1 (en) | 2017-01-27 | 2023-08-30 | The Procter & Gamble Company | Compositions in the form of dissolvable solid structures |
KR101888616B1 (en) * | 2017-02-21 | 2018-08-14 | 울산과학기술원 | Manufacturing method of flexible transparent film and flexible transparent substrate thereof |
WO2018195048A1 (en) * | 2017-04-17 | 2018-10-25 | Rowan University | Solution blow spun protein-based polymer fibers and products comprising same |
WO2018213003A1 (en) | 2017-05-16 | 2018-11-22 | The Procter & Gamble Company | Conditioning hair care compositions in the form of dissolvable solid structures |
CN108998841A (en) * | 2017-06-07 | 2018-12-14 | 南京理工大学 | A kind of preparation method of porous polypropylene nitrile nanofibre |
GB201716986D0 (en) | 2017-10-16 | 2017-11-29 | Matoke Holdings Ltd | Antimicrobial compositions |
KR102062683B1 (en) | 2018-05-23 | 2020-01-06 | 한국화학연구원 | Multilayer Film for Oxygen Barrier and Preparation Methodfor Thereof |
CN110684360A (en) * | 2018-07-04 | 2020-01-14 | 长春工业大学 | Preparation method of gelatin-based photochromic film for inkless printing |
JP1629688S (en) | 2018-07-16 | 2019-04-15 | ||
US11666514B2 (en) | 2018-09-21 | 2023-06-06 | The Procter & Gamble Company | Fibrous structures containing polymer matrix particles with perfume ingredients |
JP2022529186A (en) * | 2019-04-18 | 2022-06-17 | ナショナル・インスティテュート・オブ・テクノロジー・ルールケーラー | Self-assembled nanofibers as a hemostatic agent |
EP3993757A1 (en) | 2019-07-03 | 2022-05-11 | The Procter & Gamble Company | Fibrous structures containing cationic surfactants and soluble acids |
CN110551303B (en) * | 2019-09-17 | 2021-08-17 | 江南大学 | Method for preparing flexible conductive silk fibroin membrane by enzyme method |
USD939359S1 (en) | 2019-10-01 | 2021-12-28 | The Procter And Gamble Plaza | Packaging for a single dose personal care product |
US11597191B2 (en) | 2019-10-14 | 2023-03-07 | The Procter & Gamble Company | Biodegradable and/or home compostable sachet containing a solid article |
CN112774457B (en) * | 2019-11-01 | 2022-08-19 | 中国石油化工股份有限公司 | Polymer microfiltration membrane and preparation method and application thereof |
EP4061320A1 (en) | 2019-11-20 | 2022-09-28 | The Procter & Gamble Company | Porous dissolvable solid structure |
WO2021113211A1 (en) | 2019-12-01 | 2021-06-10 | The Procter & Gamble Company | Hair conditioner compositions with a preservation system containing sodium benzoate and glycols and/or glyceryl esters |
CN111218013B (en) * | 2020-01-22 | 2022-08-23 | 上海应用技术大学 | Preparation method and application of crosslinked polymer |
CN111549446A (en) * | 2020-03-02 | 2020-08-18 | 深圳市捷安纳米复合材料有限公司 | Virus-killing non-woven fabric, preparation process thereof and protective clothing using non-woven fabric |
USD962050S1 (en) | 2020-03-20 | 2022-08-30 | The Procter And Gamble Company | Primary package for a solid, single dose beauty care composition |
USD941051S1 (en) | 2020-03-20 | 2022-01-18 | The Procter And Gamble Company | Shower hanger |
USD965440S1 (en) | 2020-06-29 | 2022-10-04 | The Procter And Gamble Company | Package |
CN111662461A (en) * | 2020-07-10 | 2020-09-15 | 上海海洋大学 | Preparation method and application of gelatin guanidino derivative |
MX2023001043A (en) | 2020-08-11 | 2023-02-16 | Procter & Gamble | Clean rinse hair conditioner compositions containing brassicyl valinate esylate. |
EP4196233A1 (en) | 2020-08-11 | 2023-06-21 | The Procter & Gamble Company | Moisturizing hair conditioner compositions containing brassicyl valinate esylate |
WO2022036354A1 (en) | 2020-08-11 | 2022-02-17 | The Procter & Gamble Company | Low viscosity hair conditioner compositions containing brassicyl valinate esylate |
WO2022033743A1 (en) | 2020-08-14 | 2022-02-17 | Re-Organic As | Method to disperse nano-cellulose in polymers, and derived products |
MX2023005792A (en) | 2020-12-01 | 2023-05-29 | Procter & Gamble | Aqueous hair conditioner compositions containing solubilized anti-dandruff actives. |
CN112501122A (en) * | 2020-12-09 | 2021-03-16 | 河南大学 | Method for separating and extracting tumor cells |
KR20220089239A (en) * | 2020-12-21 | 2022-06-28 | 현대자동차주식회사 | Double-crosslinked cellulose nanofiber film with high strength and high transmittance and method for manufacturing the same |
CN113234260B (en) * | 2021-06-04 | 2023-06-13 | 重庆工商大学 | Preparation method of guar gum base nano composite film |
CN113445097B (en) * | 2021-07-23 | 2022-09-20 | 中国科学院青海盐湖研究所 | Fiber mesh-shaped magnesium oxide film and preparation method and application thereof |
CN113957607A (en) * | 2021-10-22 | 2022-01-21 | 内蒙古工业大学 | Nano composite protein fiber membrane mask and preparation method thereof |
CN115747992A (en) * | 2022-11-21 | 2023-03-07 | 江苏康溢臣生命科技有限公司 | High-protein-content antibacterial thermoregulation cellulose fiber and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1011516A1 (en) * | 1997-06-06 | 2000-06-28 | The Procter & Gamble Company | A delivery system for a tooth whitener using a strip of material having low flexural stiffness |
EP1022587A1 (en) * | 1997-04-04 | 2000-07-26 | Fuji Photo Film Co., Ltd. | Antireflection films and image display device containing the same |
WO2001025316A1 (en) * | 1999-10-05 | 2001-04-12 | Commonwealth Scientific And Industrial Research Organisation | Three dimensional array films |
WO2001092381A1 (en) * | 1999-12-07 | 2001-12-06 | William Marsh Rice University | Oriented nanofibers embedded in polymer matrix |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596298B2 (en) * | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
US6685956B2 (en) * | 2001-05-16 | 2004-02-03 | The Research Foundation At State University Of New York | Biodegradable and/or bioabsorbable fibrous articles and methods for using the articles for medical applications |
US20060057207A1 (en) * | 2001-11-30 | 2006-03-16 | Pfizer Inc | Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene |
WO2006106514A2 (en) * | 2005-04-06 | 2006-10-12 | Nicast Ltd. | Electrospun dosage form and method of producing the same |
US20070042023A1 (en) * | 2005-08-22 | 2007-02-22 | National Starch And Chemical Investment Holding Corporation | Dissolvable film |
US20100018641A1 (en) * | 2007-06-08 | 2010-01-28 | Kimberly-Clark Worldwide, Inc. | Methods of Applying Skin Wellness Agents to a Nonwoven Web Through Electrospinning Nanofibers |
-
2007
- 2007-08-10 KR KR20070080677A patent/KR100937625B1/en active IP Right Grant
- 2007-09-07 EP EP07808135.3A patent/EP2187970A4/en not_active Withdrawn
- 2007-09-07 US US12/672,950 patent/US20110250256A1/en not_active Abandoned
- 2007-09-07 CN CN2007801007557A patent/CN102014962B/en not_active Expired - Fee Related
- 2007-09-07 WO PCT/KR2007/004342 patent/WO2009022761A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1022587A1 (en) * | 1997-04-04 | 2000-07-26 | Fuji Photo Film Co., Ltd. | Antireflection films and image display device containing the same |
EP1011516A1 (en) * | 1997-06-06 | 2000-06-28 | The Procter & Gamble Company | A delivery system for a tooth whitener using a strip of material having low flexural stiffness |
WO2001025316A1 (en) * | 1999-10-05 | 2001-04-12 | Commonwealth Scientific And Industrial Research Organisation | Three dimensional array films |
WO2001092381A1 (en) * | 1999-12-07 | 2001-12-06 | William Marsh Rice University | Oriented nanofibers embedded in polymer matrix |
Non-Patent Citations (1)
Title |
---|
See also references of EP2187970A4 * |
Cited By (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102959148A (en) * | 2010-06-29 | 2013-03-06 | 花王株式会社 | Nanofibre laminate sheet |
CN102959148B (en) * | 2010-06-29 | 2016-07-06 | 花王株式会社 | Nanofibre laminate sheet |
US10912738B2 (en) | 2010-07-02 | 2021-02-09 | The Procter & Gamble Company | Methods of delivering an oral care active by administering oral care articles comprising a filament |
US20120172831A1 (en) * | 2010-07-02 | 2012-07-05 | Trevor John Darcy | Methods of Delivering a Health Care Active by Administering Personal Health Care Articles Comprising a Filament |
WO2012003319A3 (en) * | 2010-07-02 | 2012-02-23 | The Procter & Gamble Company | Filaments comprising an active agent nonwoven webs and methods for making same |
WO2012003367A3 (en) * | 2010-07-02 | 2012-03-01 | The Procter & Gamble Company | Method for delivering an active agent |
US20120058166A1 (en) * | 2010-07-02 | 2012-03-08 | Glenn Jr Robert Wayne | Filaments comprising a non-perfume active agent nonwoven webs and methods for making same |
WO2012003351A3 (en) * | 2010-07-02 | 2012-05-10 | The Procter & Gamble Company | Web material and method for making same |
WO2012003360A3 (en) * | 2010-07-02 | 2012-05-18 | The Procter & Gamble Company | Detergent product |
US11970789B2 (en) | 2010-07-02 | 2024-04-30 | The Procter & Gamble Company | Filaments comprising an active agent nonwoven webs and methods for making same |
US11964059B2 (en) | 2010-07-02 | 2024-04-23 | The Procter & Gamble Company | Methods of delivering an oral care active by administering oral care articles comprising a filament |
US20120237576A1 (en) * | 2010-07-02 | 2012-09-20 | Gregory Charles Gordon | Filaments comprising an active agent nonwoven webs and methods for making same |
US11944693B2 (en) | 2010-07-02 | 2024-04-02 | The Procter & Gamble Company | Method for delivering an active agent |
US11944696B2 (en) | 2010-07-02 | 2024-04-02 | The Procter & Gamble Company | Detergent product and method for making same |
CN102959150A (en) * | 2010-07-02 | 2013-03-06 | 宝洁公司 | Filaments comprising an ingestible active agent nonwoven webs and methods for making same |
US20120027838A1 (en) * | 2010-07-02 | 2012-02-02 | Gregory Charles Gordon | Filaments comprising an ingestible active agent nonwoven webs and methods for making same |
CN102971408A (en) * | 2010-07-02 | 2013-03-13 | 宝洁公司 | Detergent product |
CN102971453A (en) * | 2010-07-02 | 2013-03-13 | 宝洁公司 | Filaments comprising a non-perfume active agent nonwoven webs and methods for making same |
CN102970987A (en) * | 2010-07-02 | 2013-03-13 | 宝洁公司 | Methods of delivering a health care active by administering personal health care articles comprising a filament |
US11434586B2 (en) | 2010-07-02 | 2022-09-06 | The Procter & Gamble Company | Filaments comprising an active agent nonwoven webs and methods for making same |
JP2013509495A (en) * | 2010-07-02 | 2013-03-14 | ザ プロクター アンド ギャンブル カンパニー | Method for making a film from a nonwoven web |
CN102985603A (en) * | 2010-07-02 | 2013-03-20 | 宝洁公司 | Filaments comprising an active agent nonwoven webs and methods for making same |
CN103003476A (en) * | 2010-07-02 | 2013-03-27 | 宝洁公司 | Web material and method for making same |
CN103025929A (en) * | 2010-07-02 | 2013-04-03 | 宝洁公司 | Filaments comprising an active agent nonwoven webs and methods for making same |
WO2012003349A3 (en) * | 2010-07-02 | 2013-04-18 | The Procter & Gamble Company | Dissolvable fibrous web structure article comprising active agents |
JP2013532171A (en) * | 2010-07-02 | 2013-08-15 | ザ プロクター アンド ギャンブル カンパニー | Dissolvable fibrous web structure article containing an active agent |
CN103282015A (en) * | 2010-07-02 | 2013-09-04 | 宝洁公司 | Dissolvable fibrous web structure article comprising active agents |
US20130253017A1 (en) * | 2010-07-02 | 2013-09-26 | The Procter & Gamble Company | Methods of Delivering a Health Care Active by Administering Personal Health Care Articles Comprising a Filmament |
US8785361B2 (en) | 2010-07-02 | 2014-07-22 | The Procter & Gamble Company | Detergent product and method for making same |
JP2014237655A (en) * | 2010-07-02 | 2014-12-18 | ザ プロクター アンド ギャンブルカンパニー | Dissolvable fibrous web structure article comprising active agents |
AU2011272839B2 (en) * | 2010-07-02 | 2015-04-02 | The Procter & Gamble Company | Methods of delivering a health care active by administering personal health care articles comprising a filament |
US11021812B2 (en) | 2010-07-02 | 2021-06-01 | The Procter & Gamble Company | Filaments comprising an ingestible active agent nonwoven webs and methods for making same |
RU2553295C2 (en) * | 2010-07-02 | 2015-06-10 | Дзе Проктер Энд Гэмбл Компани | Detergent and methods of its production |
US20210154150A1 (en) * | 2010-07-02 | 2021-05-27 | The Procter & Gamble Company | Methods Of Delivering An Oral Care Active by Administering Oral Care Articles Comprising A Filament |
US9074305B2 (en) | 2010-07-02 | 2015-07-07 | The Procter & Gamble Company | Method for delivering an active agent |
RU2555042C2 (en) * | 2010-07-02 | 2015-07-10 | Дзе Проктер Энд Гэмбл Компани | Method of active substance delivery |
US9163205B2 (en) | 2010-07-02 | 2015-10-20 | The Procter & Gamble Company | Process for making films from nonwoven webs |
US9175250B2 (en) | 2010-07-02 | 2015-11-03 | The Procter & Gamble Company | Fibrous structure and method for making same |
JP2016000812A (en) * | 2010-07-02 | 2016-01-07 | ザ プロクター アンド ギャンブルカンパニー | Detergent product |
CN105332075A (en) * | 2010-07-02 | 2016-02-17 | 宝洁公司 | Filaments comprising active agent nonwoven webs and methods for making same |
CN102971408B (en) * | 2010-07-02 | 2016-03-02 | 宝洁公司 | Betengent product |
WO2012003350A1 (en) * | 2010-07-02 | 2012-01-05 | The Procter & Gamble Company | Methods of delivering a health care active by administering personal health care articles comprising a filament |
WO2012003365A1 (en) * | 2010-07-02 | 2012-01-05 | The Procter & Gamble Company | Filaments comprising an ingestible active agent nonwoven webs and methods for making same |
CN102959150B (en) * | 2010-07-02 | 2016-08-03 | 宝洁公司 | Comprise and can absorb the long filament of activating agent, non-woven webs and preparation method thereof |
US9421153B2 (en) | 2010-07-02 | 2016-08-23 | The Procter & Gamble Company | Detergent product and method for making same |
CN103282015B (en) * | 2010-07-02 | 2016-10-05 | 宝洁公司 | Comprise the soluble fiber web frame goods of activating agent |
US9480628B2 (en) | 2010-07-02 | 2016-11-01 | The Procer & Gamble Company | Web material and method for making same |
US20160374906A1 (en) * | 2010-07-02 | 2016-12-29 | The Procter & Gamble Company | Web Material and Method for Making Same |
RU2613316C1 (en) * | 2010-07-02 | 2017-03-15 | Дзе Проктер Энд Гэмбл Компани | Methods of medical active agent delivery by injection of individual health articles containing filament |
JP2017078076A (en) * | 2010-07-02 | 2017-04-27 | ザ プロクター アンド ギャンブル カンパニー | Dissolvable fibrous web structure article comprising active agents |
US10646413B2 (en) | 2010-07-02 | 2020-05-12 | The Procter & Gamble Company | Web material and method for making same |
WO2012003300A3 (en) * | 2010-07-02 | 2012-02-16 | The Procter & Gamble Company | Filaments comprising a non-perfume active agent nonwoven webs and methods for making same |
US20180015048A1 (en) * | 2010-07-02 | 2018-01-18 | The Procter & Gamble Company | Methods of Delivering a Health Care Active by Administering Personal Health Care Articles Comprising a Filmament |
US9801830B2 (en) * | 2010-07-02 | 2017-10-31 | The Procter & Gamble Company | Methods of delivering a health care active by administering personal health care articles comprising a filmament |
US10894005B2 (en) | 2010-07-02 | 2021-01-19 | The Procter & Gamble Company | Detergent product and method for making same |
US10517836B2 (en) | 2010-07-02 | 2019-12-31 | The Procter & Gamble Company | Methods of delivering a health care active by administering personal health care articles comprising a filmament |
US10449163B2 (en) | 2010-07-02 | 2019-10-22 | The Procter & Gamble Company | Methods of delivering a health care active by administering personal health care articles comprising a filament |
RU2695131C2 (en) * | 2010-07-02 | 2019-07-22 | Дзе Проктер Энд Гэмбл Компани | Filaments containing active components suitable for oral administration, non-woven fabrics and methods for production thereof |
US10045915B2 (en) | 2010-07-02 | 2018-08-14 | The Procter & Gamble Company | Method for delivering an active agent |
RU2640933C1 (en) * | 2010-07-02 | 2018-01-12 | Дзе Проктер Энд Гэмбл Компани | Filaments containing active components, suitable for oral supplementation, non-woven fabrics and methods of manufacturing them |
US9789191B2 (en) | 2010-09-13 | 2017-10-17 | Solixa Technologies, Inc. | Aqueous drug delivery system |
US9018193B2 (en) | 2010-09-13 | 2015-04-28 | Bev-Rx, Inc. | Aqueous drug delivery system |
WO2012097763A2 (en) * | 2011-01-17 | 2012-07-26 | Elmarco S.R.O. | A carrier for oromucosal, especially sublingual administration of physiologically active substances |
US11771648B2 (en) | 2011-01-17 | 2023-10-03 | Instar Technologies A.S. | Carrier for oromucosal administration of physiologically active substances |
WO2012097763A3 (en) * | 2011-01-17 | 2012-09-27 | Elmarco S.R.O. | A carrier for oromucosal, especially sublingual administration of physiologically active substances |
US9789060B2 (en) | 2011-01-17 | 2017-10-17 | Instar Technologies A.S. | Carrier for oromucosal administration of physiologically active substances |
WO2012125297A1 (en) * | 2011-03-01 | 2012-09-20 | The Procter & Gamble Company | Porous disintegratable solid substrate for personal health care applications |
WO2013035072A1 (en) * | 2011-09-08 | 2013-03-14 | Vile Glenn | Bioactive nanofibres |
EP2765160A4 (en) * | 2011-10-04 | 2015-06-17 | Genic Co Ltd | Hydrogel composition for a mask base and method for manufacturing a hydrogel using same |
US10011712B2 (en) | 2011-10-04 | 2018-07-03 | Genic Co., Ltd. | Hydrogel composition for a mask base and method for manufacturing a hydrogel using same |
US9861559B2 (en) | 2014-05-05 | 2018-01-09 | The Procter & Gamble Company | Consumer product comprising a porous, dissolvable, fibrous web solid structure with a silicone coating |
US9861558B2 (en) | 2014-05-05 | 2018-01-09 | The Procter & Gamble Company | Methods of forming an aqueous treatment liquor by dissolving a porous solid with a benefit agent coating |
US9827173B2 (en) | 2014-05-05 | 2017-11-28 | The Procter & Gamble Company | Porous dissolvable solid structure with two benefit agents and methods of forming an aqueous treatment liquor therefrom |
US9937111B2 (en) | 2014-05-05 | 2018-04-10 | The Procter & Gamble Company | Consumer product comprising a fibrous web solid structure with a silicone conditioning agent coating |
US9877899B2 (en) | 2014-05-05 | 2018-01-30 | The Procter & Gamble Company | Consumer product comprising a fibrous web structure with a silicone conditioning agent coating |
US9867762B2 (en) | 2014-05-05 | 2018-01-16 | The Procter & Gamble Company | Consumer product comprising a porous dissolvable solid structure and silicone conditioning agent coating |
CN105727358A (en) * | 2016-02-23 | 2016-07-06 | 广西易得佳医疗器械有限公司 | Drug-loaded biopolymer compound nanofiber membrane and preparation method thereof |
WO2018005571A1 (en) | 2016-06-30 | 2018-01-04 | The Gillette Company Llc | Shaving aid for razor cartridges comprising a nano-filament comprisng a core and sheath |
WO2018005148A1 (en) | 2016-06-30 | 2018-01-04 | The Gillette Company Llc | Shaving aid for razor cartridges comprising filaments |
WO2018005574A1 (en) | 2016-06-30 | 2018-01-04 | The Gillette Company Llc | Shaving aid for razor cartridges comprising a nano-filament |
RU2782456C2 (en) * | 2016-12-23 | 2022-10-27 | Контипро A.С. | Ophthalmic preparation |
CN107177049A (en) * | 2017-05-23 | 2017-09-19 | 佛山市因诺维生物科技有限公司 | A kind of HPG nano cellulose composite film and preparation method thereof |
US11753608B2 (en) | 2018-01-26 | 2023-09-12 | The Procter & Gamble Company | Water-soluble unit dose articles comprising perfume |
US11193097B2 (en) | 2018-01-26 | 2021-12-07 | The Procter & Gamble Company | Water-soluble unit dose articles comprising enzyme |
US11142730B2 (en) | 2018-01-26 | 2021-10-12 | The Procter & Gamble Company | Water-soluble articles and related processes |
US11053466B2 (en) | 2018-01-26 | 2021-07-06 | The Procter & Gamble Company | Water-soluble unit dose articles comprising perfume |
US11505379B2 (en) | 2018-02-27 | 2022-11-22 | The Procter & Gamble Company | Consumer product comprising a flat package containing unit dose articles |
US11911492B2 (en) | 2018-05-14 | 2024-02-27 | The Procter & Gamble Company | Oral care compositions comprising metal ions |
US11944694B2 (en) | 2018-05-14 | 2024-04-02 | The Procter & Gamble Company | Foaming oral care compositions |
WO2019222125A1 (en) * | 2018-05-14 | 2019-11-21 | The Procter & Gamble Company | Unit-dose oral care compositions |
US10821056B2 (en) | 2018-05-14 | 2020-11-03 | The Procter & Gamble Company | Foaming oral care compositions |
US10932996B2 (en) | 2018-05-14 | 2021-03-02 | The Procter & Gamble Company | Oral care compositions comprising fluoride ions |
US10835455B2 (en) | 2018-05-14 | 2020-11-17 | The Procter & Gamble Company | Oral care compositions comprising metal ions |
AU2019270966B2 (en) * | 2018-05-14 | 2021-11-11 | The Procter & Gamble Company | Unit-dose oral care compositions |
US10982176B2 (en) | 2018-07-27 | 2021-04-20 | The Procter & Gamble Company | Process of laundering fabrics using a water-soluble unit dose article |
US11859338B2 (en) | 2019-01-28 | 2024-01-02 | The Procter & Gamble Company | Recyclable, renewable, or biodegradable package |
US11878077B2 (en) | 2019-03-19 | 2024-01-23 | The Procter & Gamble Company | Fibrous water-soluble unit dose articles comprising water-soluble fibrous structures |
CN109966540A (en) * | 2019-04-04 | 2019-07-05 | 武汉大学 | A kind of preparation method and application of nano-chitosan compound calcium alginate medical dressing |
US11679066B2 (en) | 2019-06-28 | 2023-06-20 | The Procter & Gamble Company | Dissolvable solid fibrous articles containing anionic surfactants |
US11925698B2 (en) | 2020-07-31 | 2024-03-12 | The Procter & Gamble Company | Water-soluble fibrous pouch containing prills for hair care |
WO2023170718A1 (en) * | 2022-03-08 | 2023-09-14 | Bakel S.R.L. | Composition to be electrospun |
IT202200004418A1 (en) * | 2022-03-08 | 2023-09-08 | Bakel S R L | COMPOSITION TO BE ELECTROWIRED |
Also Published As
Publication number | Publication date |
---|---|
CN102014962B (en) | 2013-04-24 |
CN102014962A (en) | 2011-04-13 |
EP2187970A4 (en) | 2015-06-03 |
EP2187970A1 (en) | 2010-05-26 |
US20110250256A1 (en) | 2011-10-13 |
KR100937625B1 (en) | 2010-01-20 |
KR20090016203A (en) | 2009-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110250256A1 (en) | Dissolvable Nano Web Porous Film and Method of Preparing the Same | |
Torres-Martínez et al. | A summary of electrospun nanofibers as drug delivery system: Drugs loaded and biopolymers used as matrices | |
CN100389755C (en) | Compositions and methods for mucosal delivery | |
JP3293862B2 (en) | Granular pharmaceutical composition suitable for controlled release of a pharmacologically active substance and process for preparing said composition | |
CN102548535B (en) | Sublingual and buccal film compositions | |
TWI250029B (en) | Water soluble film for oral administration with instant wettability | |
Goonoo et al. | Drug loading and release from electrospun biodegradable nanofibers | |
CN1747656B (en) | Packaging and dispensing of rapid dissolve dosage form | |
US8840935B2 (en) | Orally administrable films and preparation thereof | |
EP1296661B1 (en) | Process of preparation of rapidly-decomposing administrable form for releasing active ingredients in the oral cavity or in bodily cavities | |
US20070042023A1 (en) | Dissolvable film | |
WO2005082048A2 (en) | Dissolvable film and method of manufacture | |
KR102385203B1 (en) | Sustained-release injection formulation containing bone morphogenetic protein and hyaluronic acid filler conjugate, and method for producing the same | |
CN102753196A (en) | Ph sensitive compounds in taste masking within oral thin film strips | |
AU1683988A (en) | A spun fibrous cosmetic and method of use | |
JPH03500164A (en) | Rapidly dissolving fibrous pharmaceutical composition and method for producing the same | |
TW200800305A (en) | Encapsulation of lipid-based formulations in enteric polymers | |
CN102665762A (en) | Film-like pharmaceutical dosage forms | |
JP2007091696A (en) | Soluble film | |
CN100444828C (en) | Preparation method of biodegradable polymer pharmaceutical microsphere | |
JP6444075B2 (en) | Patch | |
CN109771395A (en) | A kind of mucous membrane of mouth agent and preparation method thereof containing Quercetin | |
Sahu et al. | Nanofibers in drug delivery | |
JP2002534373A (en) | Composition containing hydroxypropylcellulose and anionic polymer, and its use as a pharmaceutical film coating | |
RU2777623C1 (en) | Injectable composition with suspended release containing a conjugate of a filler with poly-l-lactic acid, a filler with hyaluronic acid and a bioactive material, and a method for its preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780100755.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07808135 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2007808135 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007808135 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12672950 Country of ref document: US |